Hisafumi Yasuda

Hisafumi Yasuda

Auto-generated profile, based on publicly available information

Hisafumi Yasuda

Graduate School of Health Sciences, Kobe University, Kobe, Hyogo, Japan

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2011 in Clinical Immunology
Verified
Journal Article
Closed access
NTNingwen Tai
Ningwen Tai
HYHisafumi Yasuda
Hisafumi Yasuda
YXYufei Xiang
Yufei Xiang
ZLZhang Li
Zhang Li
DRDaniel Rodriguez-Pinto
Daniel Rodriguez-Pinto
LWLi Wen
Li Wen

14 December 2018 in Diabetes
Verified
Journal Article
Closed access
PDF file
YKYumiko Kawabata
Yumiko Kawabata
NNNao Nishida
Nao Nishida
TATakuya Awata
Takuya Awata
EKEiji Kawasaki
Eiji Kawasaki
AIAkihisa Imagawa
Akihisa Imagawa
HIHiroshi Ikegami
Hiroshi Ikegami
The first genome-wide association study of fulminant type 1 diabetes mellitus was performed in Japanese individuals. As previously reported using a candidate gene approach, a strong association was observed with multiple SNPs in the HLA region, and the strongest association was observed with rs9268853 in the class II DR region (P=1.56 x 10-23, odds ratio [OR] 3.18). In addition, rs11170445 in CSAD/lnc-ITGB7-1 on chromosome 12q13.13 showed an association at a genome-wide significance level (P=7.58 x 10-9, OR 1.96). Fine mapping of the region revealed that rs3782151 in CSAD/lnc-ITGB7-1 showed the lowest P value (P=4.60 x 10-9, OR 1.97 [95% CI 1.57-2.48]). The risk allele of rs3782151 is a cis-expression quantitative trait locus (eQTL) for ITGB7 that significantly increases the expression of this gene. CSAD/lnc-ITGB7-1 was found to be strongly associated with susceptibility to fulminant, but not classical, autoimmune type 1 diabetes, implicating this locus in the distinct phenotype of fulminant type 1 diabetes.

30 September 2022 in Journal of Diabetes Investigation
Verified
Journal Article
Open access
EKEiji Kawasaki
Eiji Kawasaki
ASAkira Shimada
Akira Shimada
AIAkihisa Imagawa
Akihisa Imagawa
NANorio Abiru
Norio Abiru
TATakuya Awata
Takuya Awata
HIHiroshi Ikegami
Hiroshi Ikegami
Aims/Introduction: This study aimed to investigate the clinical significance and antigen specificity of autoantibodies to insulinoma‐associated antigen‐2 (IA‐2A) by radioimmunoassay (RIA; IA‐2A‐RIA) and enzyme‐linked immunosorbent assay (ELISA; IA‐2A‐ELISA) in Japanese patients with type 1 diabetes.Materials and Methods: A total of 338 type 1 diabetic patients were enrolled, including 38 fulminant type 1 diabetes, 168 acute‐onset type 1 diabetes and 137 slowly‐progressive type 1 diabetes (SPIDDM). The concordance, correlation of autoantibody titer, and the relationship between IA‐2A and progression to the insulin‐deficient state were examined. Also, competitive assay was used to examine the antigen specificity.Results: The prevalence of IA‐2A‐ELISA was 4–5% lower than that of IA‐2A‐RIA in both the acute‐onset type 1 diabetes and SPIDDM, but the diagnostic sensitivities of both subtypes, when measured in combination with glutamic acid decarboxylase autoantibody, were comparable. The diagnosis of type 1 diabetes using either the RIA or ELISA methods showed substantial agreement with the exponential correlation of autoantibody titers detected by RIA and ELISA. Among the SPIDDM patients, the fasting C‐peptide for IA‐2A‐positive cases by ELISA, but not the RIA method, was significantly lower than in the negative cases (P < 0.05). Furthermore, IA‐2A‐ELISA proved superior to the RIA method in predicting the progression to insulin deficiency in SPIDDM. Competitive analysis showed that even sera with discrepant results by RIA and ELISA have IA‐2‐specific autoantibodies.Conclusion: These results suggest that IA‐2A‐ELISA is a reliable marker not only for the diagnosis of type 1 diabetes, but also for the prediction of future insulin dependency; that is, detection of IA‐2A‐ELISA helps identify a subtype of SPIDDM patients who would likely progress onto insulin‐deficient state.

1 June 2008 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
MSMuneaki Sakata
Muneaki Sakata
HYHisafumi Yasuda
Hisafumi Yasuda
HMHiroaki Moriyama
Hiroaki Moriyama
KYKatsumi Yamada
Katsumi Yamada
RKReiko Kotani
Reiko Kotani
MNMasao Nagata
Masao Nagata

13 June 2025 in Diabetes Care
Verified
Journal Article
Closed access
SNShinsuke Noso
Shinsuke Noso
DCDaisuke Chujo
Daisuke Chujo
AIAkihisa Imagawa
Akihisa Imagawa
EKEiji Kawasaki
Eiji Kawasaki
TATakuya Awata
Takuya Awata
TTTetsuro Tsujimoto
Tetsuro Tsujimoto
OBJECTIVE: This study aimed to investigate the progression of β-cell dysfunction and its predictors in Japanese patients with type 1 diabetes, using data from the nationwide, multicenter, prospective longitudinal Japanese Type 1 Diabetes Database Study (TIDE-J). RESEARCH DESIGN AND METHODS: TIDE-J enrolled 314 Japanese individuals with type 1 diabetes, including 165 with acute-onset, 105 with slowly progressive, and 44 with fulminant type 1 diabetes. Clinical data, including C-peptide levels, glycemic control, and autoantibody status, were collected annually for up to 14 years. HLA genotypes were analyzed at study entry. The time to insulin depletion was analyzed using survival curves and Cox proportional hazards models to determine predictive factors. RESULTS: The rate of undetectable C-peptide varied significantly among subtypes. At 5 years after onset, 43.1% (n = 55) of patients with acute-onset, 9.1% (n = 7) with slowly progressive, and 93.2% (n = 38) with fulminant type 1 diabetes reached undetectable C-peptide. Even within acute-onset type 1 diabetes, a marked interindividual variation was observed in the progression toward β-cell depletion. HLA genotypes influenced progression rates as follows: DRB1*04:05-DQB1*04:01/DRB1*04:05-DQB1*04:01 (DR4/DR4) carriers exhibited slower β-cell depletion, whereas DR4/DRB1*08:02-DQB1*03:02 (i.e., DR4/DR8) and DR4/DRB1*09:01-DQB1*03:03 (i.e., DR4/DR9) were associated with a rapid progression. For slowly progressive type 1 diabetes, low BMI, GAD antibody positivity, and absence of the DRB1*15:01-DQB1*06:02 or DRB1*15:02-DQB1*06:01 (i.e., DR2) haplotype were predictive of progression to insulin dependence. CONCLUSIONS: This study elucidates the heterogeneity in β-cell dysfunction among Japanese individuals with type 1 diabetes and identifies genetic and clinical predictors of disease progression. These findings provide insights for individualized management strategies and future therapeutic interventions.

19 February 2026 in JMIR Formative Research
Verified
Journal Article
Open access
SISatoshi Inagaki
Satoshi Inagaki
KKKenji Kato
Kenji Kato
TMTomokazu Matsuda
Tomokazu Matsuda
KAKozue Abe
Kozue Abe
HYHisafumi Yasuda
Hisafumi Yasuda
Background: Autonomous motivation, grounded in self-determination theory, is important for sustaining diabetes self-care behaviors. Although mobile health interventions, gamification, and peer support are increasingly used to enhance motivation in diabetes care, evidence on how motivation evolves over time remains limited. Specifically, it is unclear whether motivational change follows a linear pattern or a nonlinear trajectory, such as an initial increase followed by a subsequent decline. Clarifying these temporal patterns is critical for informing the design of adaptive diabetes self-care interventions. Objective: The objective of this study was to characterize the 1-year developmental trajectory of autonomous motivation following the real-world introduction of a commercially available team-based gamification app. Methods: This prospective, single-arm longitudinal study involved adults with diabetes (predominantly type 2) recruited from outpatient clinics in Japan. Participants were instructed to use a team-based gamification app designed to promote desirable habits through peer support and social comparison for at least 7 days. The primary outcome, autonomous motivation, was assessed using the Treatment Self-Regulation Questionnaire–Autonomous Motivation subscale (TSRQ-AM; score range 7-49) at baseline, 6 weeks, 6 months, and 1 year. Secondary measures included hemoglobin A1c (HbA1c), body weight, triglycerides, and psychological scales (eg, Self-Efficacy Scale for Diabetes Self-Care, Summary of Diabetes Self-Care Activities, Problem Areas in Diabetes scale, and World Health Organization–Five Well-Being Index). To analyze the trajectory, we used linear mixed-effects models with random intercepts for participants. The final model included fixed effects for time (as both linear and quadratic terms), age, sex, employment status, family structure, baseline BMI, and baseline HbA1c. Results: Of 32 consenting participants, 29 (90.6%) were included in the primary analysis; clinical data at 1 year were available for 26 (81.3%) participants. In exploratory analyses, mean TSRQ-AM scores increased from baseline (37.4, SD 7.9) to 6 months (39.5, SD 7.4; Cohen d=0.47). Over the 1-year period, body weight decreased significantly (b=−0.39; P=.01), whereas HbA1c (P=.40) and triglycerides (P=.14) showed no significant changes. The TSRQ-AM score showed a significant nonlinear change over time. A model including a quadratic time term fit significantly better than a linear-only model (χ21=4.1; P=.04), with a significant quadratic effect (b=−7.26; P=.045), indicating an inverted U-shaped trajectory peaking at 6 months. Higher baseline BMI was associated with lower TSRQ-AM scores (b=−1.00; P=.001). Conclusions: This formative study provides preliminary evidence of a nonlinear, 1-year trajectory of autonomous motivation following the introduction of a team-based app. The observed curvilinear pattern suggests that autonomous motivation during the intervention may peak at around 6 months, underscoring the importance of adaptive intervention designs to maintain engagement over time. The accompanying reduction in body weight suggests potential physiological relevance that warrants further investigation in controlled studies. Trial Registration: UMIN Clinical Trials Registry UMIN000044874; https://tinyurl.com/59bzb68k